Embed code
in the rest of Europe to be honest I
think that problem is the data quality i
think that the data quality in large
databases to study I've shown from
England included more than 60,000
patients or per year and I think in a
very large database like we have the
problem our database lots of data are
missing and I think the data quality in
other countries or in other publications
might be not not as good as an hour
population and I think this might be a
reason why the data quality the recent
years is usually better than it was like
1995-96 or in this year's when we didn't
did not focus that much on the data
quality and large databases anything to
do with saturation levels because we
know that for example the UK they had
quite low saturation levels and most
units increase them now but higher
levels
yeah maybe i'm not sure if this really
is the reason because if you look at the
data they already already started in God
increased in nineteen in 2005 and it was
usually time that point in time at least
in my experience when they increase in
situation is not already done it was
little later I think
and i would like to know you have been
comparing the treatment or the incidence
of treatment the treatment criteria the
same over Switzerland and England is it
the same basically saying yes it's
published very frequently and you know
the rapper upstages 125 there can define
quite clearly and it's pretty clear when
you have two should intervene introduced
to a treatment the problem the inner
study has shown is that in the beginning
there they had like cryotherapy and then
they moved to latest therapy and then
they moved to anti-vegf and so all the
data is little mixed and they just put
all this together in ROP treatment and
it's not really clear if it's really
isn't the same point in RP development
when they started the treatment so they
just mix it up but I think in general
the treatment criteria is basically the
same and in Europe in USA in Switzerland
do you do you change thank you for TSM
very important for TNT's nice
presentation is very short question do
you regard to your conclusions do you
adopt your management them based on oh
no no not yet so i think the results are
not reliable enough to adapt right now
that's what I think we should develop a
precise model already defined we want to
screen patients
let's say below 30 weeks or between
below 29 weeks plus patients with
additional criteria like long oxygen
application and so on and then we have
to test this product respectively and we
said if we come up after let's say 2 35
years and say we really do not miss any
patients then I think we couldn't change
the recommendation but now I think it's
too early

Share this talk: 


Conference program

Welcome Words
M. Roth-Kleiner, R. Arlettaz Mieth
10 jan. 2017 · 9:33 matin
Short Reports Introduction
E. Giannoni, T. Karen, Resp. Lausanne, Zürich
10 jan. 2017 · 9:38 matin
Association of Axonal Injury and Preeclampsia
Katrina Evers, Neonatology UKBB
10 jan. 2017 · 9:39 matin
Q&A - Association of Axonal Injury and Preeclampsia
Katrina Evers, Neonatology UKBB
10 jan. 2017 · 9:44 matin
Retinopathy of Prematurity
Roland Gerull, Bern
10 jan. 2017 · 9:47 matin
Q&A - Retinopathy of Prematurity
Roland Gerull, Bern
10 jan. 2017 · 9:54 matin
Parechovirus Infection: A Rare Cause of Neonatal Encephalitis (in French)
Dr Truant AS, Cheffe de clinique, Néonatologie, CHUV, Lausanne
10 jan. 2017 · 9:59 matin
Q&A - Parechovirus Infection: A Rare Cause of Neonatal Encephalitis
Dr Truant AS, Cheffe de clinique, Néonatologie, CHUV, Lausanne
10 jan. 2017 · 10:04 matin
Genetic Susceptibility to Neonatal Group B Streptococcal Disease
Alessandro Borghesi, Fellay lab, EPFL
10 jan. 2017 · 10:17 matin
Q&A - Genetic Susceptibility to Neonatal Group B Streptococcal Disease
Alessandro Borghesi, Fellay lab, EPFL
10 jan. 2017 · 10:25 matin
Psychomotor Development in Children Prenatally Exposed to Methadone
G. Grand-Guillaume-Perrenoud, Pediatrics, Children's University Hospital Geneva
10 jan. 2017 · 10:27 matin
Q&A - Psychomotor Development in Children Prenatally Exposed to Methadone
G. Grand-Guillaume-Perrenoud, Pediatrics, Children's University Hospital Geneva
10 jan. 2017 · 10:34 matin
Introduction to Christoph Berger's Presentation
C. Kind, R. Gerull, Resp. St.Gallen, Bern
10 jan. 2017 · 10:37 matin
Vertical Infections: An Update
Christoph Berger, Zürich
10 jan. 2017 · 10:40 matin
Q&A - Vertical Infections: An Update
Christoph Berger, Zürich
10 jan. 2017 · 11:15 matin
Introduction to Eric Giannoni's Presentation
R. Pfister, S. Kämpfen, Resp. Geneva, Basel
10 jan. 2017 · 11:44 matin
Sepsis, Antibiotics and Resistances: Where Are We?
Christoph Bührer, Berlin
10 jan. 2017 · 2:21 après-midi
Use and Abuse of Antibiotics in Neonatology
Martin Stocker, Lucerne
10 jan. 2017 · 2:50 après-midi
Panel Discussion : Controversies on Use of Antibiotics in Neonatology
Martin Stocker, Christoph Berger, Eric Giannoni, Christoph Bührer
10 jan. 2017 · 3:10 après-midi
Introduction to Christoph Bührer's Presentation
Romaine Arlettaz Mieth , Neonatologist, Zürich, President of the Organizing Committee
10 jan. 2017 · 3:47 après-midi
Evidence-Based Haemodynamic Management in Neonatal Sepsis
Christoph Bührer, Berlin
10 jan. 2017 · 3:48 après-midi
Q&A - Evidence-Based Haemodynamic Management in Neonatal Sepsis
Christoph Bührer, Berlin
10 jan. 2017 · 4:16 après-midi
SwissNeoDose Project
Marc Pfister, Ped Pharmacology, UKBB
10 jan. 2017 · 4:20 après-midi
Awards (Case of the Year; Milupa; Best Poster Case Report; Best Oral Short Presentation) & Closing Comments
Matthias Roth-Kleiner, CHUV, President of the SSN
10 jan. 2017 · 4:30 après-midi